- Home
- HNVR vs CRDF Comparison
HNVR vs CRDF Comparison
Compare HNVR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- CRDF
- Stock Information
- Founded
- HNVR 2008
- CRDF 1999
- Country
- HNVR United States
- CRDF United States
- Employees
- HNVR N/A
- CRDF N/A
- Industry
- HNVR Commercial Banks
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNVR Finance
- CRDF Health Care
- Exchange
- HNVR Nasdaq
- CRDF Nasdaq
- Market Cap
- HNVR 164.7M
- CRDF 169.6M
- IPO Year
- HNVR 2022
- CRDF N/A
- Fundamental
- Price
- HNVR $21.48
- CRDF $3.18
- Analyst Decision
- HNVR Buy
- CRDF Strong Buy
- Analyst Count
- HNVR 1
- CRDF 4
- Target Price
- HNVR $22.00
- CRDF $12.25
- AVG Volume (30 Days)
- HNVR 11.9K
- CRDF 1.3M
- Earning Date
- HNVR 07-23-2025
- CRDF 08-07-2025
- Dividend Yield
- HNVR 1.84%
- CRDF N/A
- EPS Growth
- HNVR N/A
- CRDF N/A
- EPS
- HNVR 1.31
- CRDF N/A
- Revenue
- HNVR $65,041,000.00
- CRDF $587,000.00
- Revenue This Year
- HNVR N/A
- CRDF N/A
- Revenue Next Year
- HNVR $13.69
- CRDF N/A
- P/E Ratio
- HNVR $16.40
- CRDF N/A
- Revenue Growth
- HNVR 5.06
- CRDF N/A
- 52 Week Low
- HNVR $15.92
- CRDF $2.01
- 52 Week High
- HNVR $27.14
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- HNVR 42.03
- CRDF 41.74
- Support Level
- HNVR $20.79
- CRDF $2.98
- Resistance Level
- HNVR $21.93
- CRDF $3.99
- Average True Range (ATR)
- HNVR 0.50
- CRDF 0.29
- MACD
- HNVR -0.11
- CRDF -0.08
- Stochastic Oscillator
- HNVR 36.22
- CRDF 5.34
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.